It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.<\/p>\n
Tildrakizumab was approved by the Food and Drug Administration in March 2018, and the European Medicines Agency in September 2018, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.\u00a0Tildrakizumab is administered via subcutaneous injection. It is available as a single-dose prefilled syringe containing 100 mg of tildrakizumab in 1 ml of solution.<\/p>\n
If tildrakizumab-asmn injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
ILUMYA (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 2018<\/p>\n
tildrakizumab-asmn injectionis an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.<\/p>\n
DISEASE INDICATIONS-Psoriasis If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201ctildrakizumab-asmn injection\u201d based on the information you provide.<\/p>\n
\nMANUFACTURER-Almirall, S.A.
\nUSAGE-Subcutaneous
\nMEDICINE APPROVED BY-European Medical Agency (EMA),Food and Drug Administration (FDA).
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n